TherapeuticsMD, Inc. (NYSE: TXMD) announced positive top-line results from its pivotal phase 3 Replenish Trial of TX-001HR, an investigational bio-identical ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE